Insider Transactions in Q2 2022 at C4 Therapeutics, Inc. (CCCC)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 25
2022
|
Andrew Hirsch President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+35.71%
|
-
|
|
May 25
2022
|
Scott N Boyle Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
-
|
|
May 25
2022
|
Lauren White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
-
|
|
May 25
2022
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+4.75%
|
-
|
|
May 25
2022
|
Kelly Schick Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
-
|
|
May 25
2022
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+16.67%
|
-
|
|
May 25
2022
|
Jolie Siegel Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+50.0%
|
-
|
|
Apr 12
2022
|
Andrew Hirsch President & CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$80,000
$8.4 P/Share
|
|
Apr 12
2022
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,084
+15.59%
|
$112,336
$4.35 P/Share
|
|
Apr 04
2022
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
341
+0.38%
|
$8,866
$26.46 P/Share
|
|
Apr 04
2022
|
Alain J Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+29.48%
|
$10,088
$26.46 P/Share
|
|
Apr 04
2022
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
379
+30.27%
|
$9,854
$26.46 P/Share
|